Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Null hypothesis: 10 IU Oxytocin is better than sublingual misoprostol 600µg in management of third stage of labor Alternative hypothesis: Sublingual misoprostol 600µg is non- inferior to 10 IU oxytocin and will not be more than 6% worse [than 10 IU oxytocin] in management of third stage of labor

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mbarara University of Science and Technology
• Collaborators: Makerere University; University Ghent
• Treatments: Misoprostol

Criteria

Inclusion Criteria:Term mothers [38-41 WOA] above 18 years of age admitted at Mbarara Hospital, Uganda in active labor; anticipating vaginal delivery -

Exclusion Criteria:

Complicated labor:

1. confirmed intra-uterine fetal death

2. self-reported maternal heart disease

3. current diagnosis of severe malaria or acute bacterial infection,

4. multiple pregnancy,

5. induced or augmented labor,

6. elective Caesarean section,

7. ante-partum hemorrhage,

8. reported hypersensitivity to prostaglandins

9. altered cognitive status (ACS) as assessed by the MRAs. -